Colossal Biosciences Acquires Viagen, the Leader in Animal Cloning
Colossal Biosciences, a Dallas-based biotechnology company focused on de-extinction and species restoration, has announced its acquisition of Viagen Pets and Equine, the global leader in animal cloning for pets, equine and endangered species. The acquisition brings Viagen’s high-efficiency cloning and cryopreservation technologies under Colossal’s portfolio, enabling expanded efforts in endangered species recovery and genetic preservation. Viagen will continue to operate as a Texas-based subsidiary under its current leadership while integrating into Colossal’s broader mission to restore biodiversity. 
Colossal Biosciences Acquires Viagen, the Leader in Animal Cloning